Regeneron Pharmaceuticals said the US FDA has rejected approval of its blood cancer therapy for two forms of lymphoma, raising concerns about the progress of ongoing confirmatory trials. The FDA said it needed more data from enrolments in the dose-finding and confirmatory portions of the trials.